Prostaglandin inhibitors, such as celecoxib (Celebrex, Pfizer) and indomethacin (Indocin, Merck and Lundbeck) and calcium channel blockers, such as nifedipine and nicardipine (Cardene, Cornerstone Therapeutics) had the highest probability of delaying premature labor by 48 hours and improving maternal and neonatal outcomes, according to a systemic review and network meta-analysis published in a recent issue of BMJ.
FDA Issues Complete Response Letter for Pz-Cel to Treat Epidermolysis Bullosa
April 22nd 2024Prademagene zamikeracel is a cell therapy designed to incorporate the functional collagen-producing COL7A1 gene into a patient’s own skin cells. The FDA is asking for additional information on manufacturing practices.
Read More
FDA Approves Stelara Biosimilar, Selarsdi
April 18th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
Read More